GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OSTO:KARO BTA) » Definitions » Gross Margin %

Karo Pharma AB (OSTO:KARO BTA) Gross Margin % : 0.00% (As of Jun. 2022)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Karo Pharma AB's Gross Profit for the three months ended in Jun. 2022 was kr0 Mil. Karo Pharma AB's Revenue for the three months ended in Jun. 2022 was kr0 Mil. Therefore, Karo Pharma AB's Gross Margin % for the quarter that ended in Jun. 2022 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Karo Pharma AB's Gross Margin % or its related term are showing as below:

OSTO:KARO BTA' s Gross Margin % Range Over the Past 10 Years
Min: 41.39   Med: 51.99   Max: 58.12
Current: 57.62


During the past 13 years, the highest Gross Margin % of Karo Pharma AB was 58.12%. The lowest was 41.39%. And the median was 51.99%.

OSTO:KARO BTA's Gross Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 47.02 vs OSTO:KARO BTA: 57.62

Karo Pharma AB had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Karo Pharma AB was 4.50% per year.


Karo Pharma AB Gross Margin % Historical Data

The historical data trend for Karo Pharma AB's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Gross Margin % Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.99 58.12 51.76 55.34 57.62

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.94 56.29 56.41 56.98 -

Competitive Comparison of Karo Pharma AB's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karo Pharma AB's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's Gross Margin % falls into.



Karo Pharma AB Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Karo Pharma AB's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=1706.3 / 2961.353
=(Revenue - Cost of Goods Sold) / Revenue
=(2961.353 - 1255.028) / 2961.353
=57.62 %

Karo Pharma AB's Gross Margin for the quarter that ended in Jun. 2022 is calculated as


Gross Margin % (Q: Jun. 2022 )=Gross Profit (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Karo Pharma AB  (OSTO:KARO BTA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Karo Pharma AB had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Karo Pharma AB Gross Margin % Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (OSTO:KARO BTA) Business Description

Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (OSTO:KARO BTA) Headlines

No Headlines